Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TEV-56278 · 1 trial · 1 indication
CTCAE: Common Terminology Criteria for Adverse Events
DLT: dose-limiting toxicity
RECIST: Response Evaluation Criteria in Solid Tumors.
| Arm | Type | Description |
|---|---|---|
| TEV-56278 Monotherapy; Dose Escalation | EXPERIMENTAL | - |
| TEV-56278 Monotherapy; Dose Expansion | EXPERIMENTAL | - |
| TEV-56278 in Combination with Pembrolizumab; Dose Escalation | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| TEV-56278 | DRUG | Administered intravenously |
| Pembrolizumab | DRUG | Administered intravenously |
Inclusion Criteria: * Have an established histological diagnosis of selected solid tumor and must have received and progressed on established standard therapies or have been intolerant to such therapy or have been considered by the Investigator as ineligible for approved standard therapy * Have a l...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
TEV-56278 is an investigational small molecule oncology drug being developed by Teva Pharmaceutical Industries Limited for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development and is not yet approved for any indication. It is being studied both as a single agent and in combination with pembrolizumab.
TEV-56278 is being studied for the treatment of advanced or metastatic solid tumors. The Phase 1 trial enrolls adults with advanced solid tumors, and the drug is evaluated alone or in combination with pembrolizumab. It remains investigational and has not been approved for commercial use in any cancer type.
TEV-56278 is being developed by Teva Pharmaceutical Industries Limited, which trades on the New York Stock Exchange under the ticker TEVA. Teva is the sponsor of the clinical program evaluating the drug in advanced solid tumors.
TEV-56278 is in Phase 1 clinical development. The program consists of one active, recruiting trial in advanced or metastatic solid tumors. The study is an open-label dose escalation and expansion trial, and the drug has not been approved by the FDA or any other regulatory agency.
TEV-56278 is being evaluated in the Phase 1 trial NCT06480552, titled an open-label dose escalation and expansion trial of TEV-56278 alone or in combination with pembrolizumab in participants with advanced or metastatic solid tumors. The trial is recruiting, plans to enroll 240 participants, and is running in the United States and Canada.
Yes. The Phase 1 trial NCT06480552 uses a controlled design, though it is open label rather than double blind. It is a randomized dose escalation and expansion study enrolling 240 adults aged 18 years and older with advanced or metastatic solid tumors, and it does not select patients by biomarker.